- Home
- KIDS vs OMER Comparison
KIDS vs OMER Comparison
Compare KIDS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | OMER |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 628.9M |
| IPO Year | 2017 | 2009 |
Fundamental Metrics
Financial Performance| Metric | KIDS | OMER |
|---|---|---|
| Price | $17.58 | $16.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $24.75 | ★ $27.50 |
| AVG Volume (30 Days) | 156.0K | ★ 3.5M |
| Earning Date | 10-28-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,410,000.00 | N/A |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $12.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.90 | N/A |
| 52 Week Low | $15.28 | $2.95 |
| 52 Week High | $27.60 | $17.65 |
Technical Indicators
Market Signals| Indicator | KIDS | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 73.84 |
| Support Level | $17.07 | $8.60 |
| Resistance Level | $18.04 | $17.47 |
| Average True Range (ATR) | 0.66 | 1.26 |
| MACD | -0.01 | 0.69 |
| Stochastic Oscillator | 38.89 | 87.37 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.